CoNCERT is creating new medicines through a novel scientific approach utilizing the naturally-occurring element deuterium. It applies its innovative platform to modify specific properties of validated drug molecules, yielding a rich pipeline of new chemical entities. CoNCERT leverages decades of pharmaceutical experience to create drug candidates with potential for best-in-class efficacy and safety, while greatly reducing R&D risk, time and expense. The Company has over 100 patent applications for new drug candidates addressing a broad range of therapeutic areas, including hot flashes, fibrotic diseases, pain and infectious disease.
Co-investors include Adage Capital Management L.P., SR One Ltd., Westfield
Capital Management, Three Arch Partners, TVM Capital, Skyline Ventures,
Brookside Capital Partners Fund, LP, Flagship Ventures, Greylock Partners,
New Leaf Venture Partners, and QVT Fund LP. Paul Howard is a Board observer.
DiscoveRx develops a portfolio of high
performance biochemical reagents for use in a broad range of drug discovery
assays. These assays include drug lead identification in high throughput
screening as well as drug target identification and validation in proteomic
and genomic studies.
Co-investors in the company include Skyline Ventures, Morgan Stanley
Ventures and Alta Partners. Paul Howard is a Board observer.
PatientKeeper develops software for
hand-held devices (PDAs) for physicians and allied health personnel.
Applications include charge capture, clinical results, prescriptions and
dictation. The company also provides a sophisticated back-end database and
synchronizing capability. PatientKeeper’s customers comprise more than 300
hospitals, including major teaching hospitals and community hospital
Co-investors include NEA, Frazier and Co. and J.H. Whitney and Co. Larry
Miller is a member of the Board.
Relypsa, Inc. is a biopharmaceutical company leading the discovery and development of new non-absorbed polymeric drugs for important applications in cardiovascular and renal disease. The new company is a spin-out of Ilypsa, Inc., a wholly-owned subsidiary of Amgen, Inc. (acquired by Amgen in July 2007 for $ 420 M). Relypsa commenced operations with rights to a proprietary drug discovery platform and a pipeline of product candidates, including a potassium binder drug candidate for the treatment of hyperkalemia, known as RLY5016, as well as a novel sodium binder, RLY102, for the potential treatment of congestive heart failure. RLY 5016 is currently in phase II trials. Relypsa is dedicated to discovering additional product candidates through use of its proprietary polymer platform.
Co-investors include, 5AM Ventures, New Leaf and Delphi. Paul Howard is a Board observer.
STARTech is a Dallas-based "accelerator"
providing early stage companies with a broad range of financial, legal and
administrative assistance, including the services of experienced "mentors"
who can provide direct tactical and strategic advice. The company focuses on
information technology approaches to health care and other sectors.
Co-investors include Sevin Rosen, InterWest Partners, Rho Management and
Supplemental provides staffing services to
hospitals and other health care facilities, including traveling and local
staffing of nurses and ancillary hospital personnel, such as radiology
technicians, physical therapists, and occupational therapists. Supplemental
is one of the top ten nurse and therapist staffing companies in the U.S.
Co-investors include GE Capital and Dauphin Capital Partners. Paul Howard is
a member of the Board.
Tetraphase Pharmaceuticals was founded by
Mediphase. Tetraphase develops antibiotics in the tetracycline class, based
on synthetic technology developed by Prof. Andrew Myers and licensed from
Co-investors include Fidelity Biosciences, Skyline Ventures, Flagship
Ventures and CMEA Ventures. Larry Miller is Board Chairman.
Wellpartner is a pharmacy benefit manager (PBM)
focusing on mail order drug delivery, primarily in Medicaid plans. The
recent financing will support significant expansion of capacity and
sales/marketing. We believe that the management has unusual expertise in the
complex Medicaid arena, and the company is poised for rapid growth over the
next 24 months.
Co-investors include 3i Technology Partners, Integra Ventures, and Buerk
Dale Victor. Paul Howard is a Board observer.
HMS develops healthcare data sets which support customer targeting, resource allocation and new ways to track and measure ROI. HMS solutions span licensing of databases, building custom data sets, and providing data matching, integration, and integrity validation services.
HMS was acquired by a group of investors in October 2007.
In May, 2010, Roxro Pharma’s product, intranasal analgesic SPRIX™, was approved by the FDA for treatment of acute pain.
Roxro was acquired by Luitpold Pharmaceuticals in December, 2010.
Serenex was founded by Mediphase. Serenex develops therapeutics to both treat the primary causes of cancer as well to treat the side effects associated with the use of chemotherapeutic agents. The company was acquired by Pfizer in April 2008.
Targanta is developing antibiotics for the treatment of serious infections. The company was acquired by The Medicines Company in February 2009.
Triad Therapeutics, Inc.
San Diego, CA
Triad develops targeted drug candidates through NMR spectroscopy guided
techniques. In December 2004, the company completed an asset sale
transaction with Novartis to develop and market Triad’s drug candidates.
Xenoport (NASDAQ: XNPT) develops technology to improve the oral absorption and pharmacokinetic properties of drugs, using active transport systems found in the human gastrointestinal tract. Xenoport has reported successful Phase II trials with a pro-drug of gabapentin (Neurontin) for use in treating restless legs syndrome, and will begin Phase III trials in late 2006. A second pro-drug, Baclofen, recently completed Phase II clinical trials for the treatment GERD.
Zyomyx has developed an extensive
collection of proprietary technologies for the production and analysis of
protein arrays. The company is outlicensing these technologies through a
number of commercial contract R&D arrangements.